Trial site
University of Louisville - James Graham Brown Cancer Center
Louisville, Kentucky 40202, United StatesNot linked to an institution yet
- 6running trials
- 9closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 28 trials
- Phase 34 trials
- Phase 1/21 trial
- Status
- Completed7 trials
- Active, not recruiting6 trials
- Withdrawn2 trials
- Lead sponsor
- Amgen2 trials
- Iovance Biotherapeutics, Inc.2 trials
- Bexion Pharmaceuticals, Inc.1 trial
- Elephas1 trial
- Greg Durm, MD1 trial
- and 8 more
Closed trials
Recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904· Phase 3· Iovance Biotherapeutics, Inc.· Source
Contact: Iovance Biotherapeutics Study Team
Completed
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT04919512· Phase 2· Janssen Research & Development, LLC· Source
Completed
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
NCT04471844· NovoCure Ltd.· Source
Completed
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
NCT04068181· Phase 2· Amgen· Source
Completed
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT03781063· Phase 2· Sermonix Pharmaceuticals Inc.· Source
Withdrawn
Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer
NCT03419559· Phase 2· Iovance Biotherapeutics, Inc.· Source
Completed
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
NCT03285321· Phase 2· Greg Durm, MD· Source
Completed
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
NCT03056755· Phase 2· Novartis Pharmaceuticals· Source
Completed
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
NCT02831959· Phase 3· NovoCure GmbH· Source
Report an error